<DOC>
	<DOCNO>NCT01047358</DOCNO>
	<brief_summary>This non-interventional study monitor use real practice Korea include adverse event Aromasin ( Exemestane ) .</brief_summary>
	<brief_title>Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer</brief_title>
	<detailed_description>All case participate institution .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Postmenopausal woman breast cancer eligible hormonal therapy . Pregnant breastfeeding premenopausal .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>